ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
investment factor · long-only model fund

Foundry Investment Discipline Industry-Neutral Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FINRHYPOTHETICAL MODEL
Since ’99
+67%
Expense Ratio
0.35%
placeholder
Holdings
261
cap-weighted
Inception
Mar 2020
placeholder
Full Sharpe
0.20
Ann. Return (LS)
3.2%
Ann. Volatility
16.2%
Max Drawdown
-54.8%
Test Sharpe ’19–26
-0.04
Test FF5 α (ann.)
1.3%
vs Fama-French 5
Test FF5 α t-stat
0.19
not significant
Monthly turnover
31%
of the long leg, per rebalance
Cumulative return (LS)
67%
over 331 months
This fund holds the long leg only
Long leg Sharpe
0.54
what this fund holds
Long leg ann. return
9.1%
buyable, long-only
Long-short Sharpe
0.20
requires shorting
Bottom bucket ann. return
6.0%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

331 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

261 of 261 · 100.0% of book
TickerCompanySectorMarket capWeight
1LLY
ELI LILLY & COHealthcare$1.11T
24.14%
2JNJ
JOHNSON & JOHNSONHealthcare$609.12B
13.24%
3ABBV
ABBVIE INCHealthcare$449.63B
9.78%
4MRK
MERCK & CO INCHealthcare$314.90B
6.85%
5AMGN
AMGEN INCHealthcare$197.69B
4.30%
6ABT
ABBOTT LABORATORIESHealthcare$175.37B
3.81%
7GILD
GILEAD SCIENCES INCHealthcare$166.72B
3.62%
8PFE
PFIZER INCHealthcare$142.77B
3.10%
9BMY
BRISTOL MYERS SQUIBB COHealthcare$124.04B
2.70%
10VRTX
VERTEX PHARMACEUTICALS INCHealthcare$123.26B
2.68%
11REGN
REGENERON PHARMACEUTICALS INCHealthcare$70.94B
1.54%
12IDXX
IDEXX LABORATORIES INCHealthcare$44.76B
0.97%
13CBRE
CBRE GROUP INCReal Estate$41.28B
0.90%
14RVMD
REVOLUTION MEDICINES INCHealthcare$39.58B
0.86%
15TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTDHealthcare$37.30B
0.81%
16ALNY
ALNYLAM PHARMACEUTICALS INCHealthcare$35.71B
0.78%
17ONC
BEONE MEDICINES LTDHealthcare$34.68B
0.75%
18RPRX
ROYALTY PHARMA PLCHealthcare$33.50B
0.73%
19ZTS
ZOETIS INCHealthcare$32.10B
0.70%
20BIIB
BIOGEN INCHealthcare$30.41B
0.66%
21ROIV
ROIVANT SCIENCES LTDHealthcare$24.82B
0.54%
22MRNA
MODERNA INCHealthcare$24.53B
0.53%
23INSM
INSMED INCHealthcare$23.48B
0.51%
24UTHR
UNITED THERAPEUTICS CORPHealthcare$22.74B
0.49%
25VTRS
VIATRIS INCHealthcare$20.14B
0.44%
26INVH
INVITATION HOMES INCReal Estate$17.89B
0.39%
27NBIX
NEUROCRINE BIOSCIENCES INCHealthcare$17.18B
0.37%
28BBIO
BRIDGEBIO PHARMA INCHealthcare$15.94B
0.35%
29JAZZ
JAZZ PHARMACEUTICALS PLCHealthcare$15.53B
0.34%
30JLL
JONES LANG LASALLE INCReal Estate$15.34B
0.33%
31CDE
COEUR MINING INCBasic Materials$14.85B
0.32%
32ELAN
ELANCO ANIMAL HEALTH INCHealthcare$12.90B
0.28%
33MDGL
MADRIGAL PHARMACEUTICALS INCHealthcare$12.76B
0.28%
34AXSM
AXSOME THERAPEUTICS INCHealthcare$11.84B
0.26%
35BMRN
BIOMARIN PHARMACEUTICAL INCHealthcare$11.52B
0.25%
36TECH
BIO-TECHNE CORPHealthcare$11.29B
0.25%
37SMMT
SUMMIT THERAPEUTICS INCHealthcare$10.72B
0.23%
38ARWR
ARROWHEAD PHARMACEUTICALS INCHealthcare$10.47B
0.23%
39KRYS
KRYSTAL BIOTECH INCHealthcare$10.46B
0.23%
40APGE
APOGEE THERAPEUTICS INCHealthcare$10.10B
0.22%
41CYTK
CYTOKINETICS INCHealthcare$9.98B
0.22%
42CORT
CORCEPT THERAPEUTICS INCHealthcare$9.72B
0.21%
43KYMR
KYMERA THERAPEUTICS INCHealthcare$9.52B
0.21%
44HALO
HALOZYME THERAPEUTICS INCHealthcare$9.23B
0.20%
45PTGX
PROTAGONIST THERAPEUTICS INCHealthcare$9.06B
0.20%
46IONS
IONIS PHARMACEUTICALS INCHealthcare$8.99B
0.20%
47CRNX
CRINETICS PHARMACEUTICALS INCHealthcare$8.84B
0.19%
48ALKS
ALKERMES PLCHealthcare$8.79B
0.19%
49TGTX
TG THERAPEUTICS INCHealthcare$8.40B
0.18%
50RGEN
REPLIGEN CORPHealthcare$8.31B
0.18%
51IMVT
IMMUNOVANT INCHealthcare$8.27B
0.18%
52PCVX
VAXCYTE INCHealthcare$8.12B
0.18%
53IBRX
IMMUNITYBIO INCHealthcare$8.04B
0.17%
54TRNO
TERRENO REALTY CORPReal Estate$7.98B
0.17%
55MIRM
MIRUM PHARMACEUTICALS INCHealthcare$7.25B
0.16%
56LNTH
LANTHEUS HOLDINGS INCHealthcare$7.00B
0.15%
57RIOT
RIOT PLATFORMS INCFinancial Services$6.91B
0.15%
58COGT
COGENT BIOSCIENCES INCHealthcare$6.68B
0.15%
59XENE
XENON PHARMACEUTICALS INCHealthcare$6.60B
0.14%
60PTCT
PTC THERAPEUTICS INCHealthcare$6.52B
0.14%
61CGON
CG ONCOLOGY INCHealthcare$6.34B
0.14%
62SRRK
SCHOLAR ROCK HOLDING CORPHealthcare$6.33B
0.14%
63LGND
LIGAND PHARMACEUTICALS INCHealthcare$6.08B
0.13%
64ERAS
ERASCA INCHealthcare$5.96B
0.13%
65TWST
TWIST BIOSCIENCE CORPHealthcare$5.84B
0.13%
66DNTH
DIANTHUS THERAPEUTICS INCHealthcare$5.77B
0.13%
67AMRX
AMNEAL PHARMACEUTICALS INCHealthcare$5.69B
0.12%
68ORKA
ORUKA THERAPEUTICS INCHealthcare$5.59B
0.12%
69TVTX
TRAVERE THERAPEUTICS INCHealthcare$5.27B
0.11%
70KNSA
KINIKSA PHARMACEUTICALS INTERNATIONAL PLCHealthcare$4.92B
0.11%
71CRSP
CRISPR THERAPEUTICS AGHealthcare$4.61B
0.10%
72ACAD
ACADIA PHARMACEUTICALS INCHealthcare$4.38B
0.10%
73EWTX
EDGEWISE THERAPEUTICS INCHealthcare$4.28B
0.09%
74TNGX
TANGO THERAPEUTICS INCHealthcare$4.13B
0.09%
75DYN
DYNE THERAPEUTICS INCHealthcare$3.92B
0.09%
76CPRX
CATALYST PHARMACEUTICALS INCHealthcare$3.85B
0.08%
77RLAY
RELAY THERAPEUTICS INCHealthcare$3.81B
0.08%
78DNLI
DENALI THERAPEUTICS INCHealthcare$3.70B
0.08%
79ADPT
ADAPTIVE BIOTECHNOLOGIES CORPHealthcare$3.67B
0.08%
80ALMS
ALUMIS INCHealthcare$3.65B
0.08%
81ARQT
ARCUTIS BIOTHERAPEUTICS INCHealthcare$3.56B
0.08%
82OGN
ORGANON & COHealthcare$3.55B
0.08%
83JOE
ST JOE COReal Estate$3.48B
0.08%
84GPCR
STRUCTURE THERAPEUTICS INCHealthcare$3.45B
0.07%
85RCUS
ARCUS BIOSCIENCES INCHealthcare$3.44B
0.07%
86VAC
MARRIOTT VACATIONS WORLDWIDE CORPConsumer Cyclical$3.43B
0.07%
87ELVN
ENLIVEN THERAPEUTICS INCHealthcare$3.24B
0.07%
88IDYA
IDEAYA BIOSCIENCES INCHealthcare$3.16B
0.07%
89UE
URBAN EDGE PROPERTIESReal Estate$2.99B
0.06%
90IRON
DISC MEDICINE INCHealthcare$2.91B
0.06%
91RARE
ULTRAGENYX PHARMACEUTICAL INCHealthcare$2.88B
0.06%
92BEAM
BEAM THERAPEUTICS INCHealthcare$2.83B
0.06%
93SUPN
SUPERNUS PHARMACEUTICALS INCHealthcare$2.79B
0.06%
94CLDX
CELLDEX THERAPEUTICS INCHealthcare$2.77B
0.06%
95NMRK
NEWMARK GROUP INCReal Estate$2.77B
0.06%
96VERA
VERA THERAPEUTICS INCHealthcare$2.76B
0.06%
97TRVI
TREVI THERAPEUTICS INCHealthcare$2.71B
0.06%
98KOD
KODIAK SCIENCES INCHealthcare$2.67B
0.06%
99ATAI
ATAIBECKLEY INCHealthcare$2.66B
0.06%
100TARS
TARSUS PHARMACEUTICALS INCHealthcare$2.58B
0.06%
101QURE
UNIQURE NVHealthcare$2.54B
0.06%
102IMNM
IMMUNOME INCHealthcare$2.53B
0.05%
103NRIX
NURIX THERAPEUTICS INCHealthcare$2.40B
0.05%
104VCEL
VERICEL CORPHealthcare$2.38B
0.05%
105PBH
PRESTIGE CONSUMER HEALTHCARE INCHealthcare$2.36B
0.05%
106BCRX
BIOCRYST PHARMACEUTICALS INCHealthcare$2.36B
0.05%
107AGIO
AGIOS PHARMACEUTICALS INCHealthcare$2.36B
0.05%
108BHVN
BIOHAVEN LTDHealthcare$2.32B
0.05%
109NKTR
NEKTAR THERAPEUTICSHealthcare$2.31B
0.05%
110NEOG
NEOGEN CORPHealthcare$2.24B
0.05%
111MLYS
MINERALYS THERAPEUTICS INCHealthcare$2.23B
0.05%
112IOVA
IOVANCE BIOTHERAPEUTICS INCHealthcare$2.23B
0.05%
113GTY
GETTY REALTY CORPReal Estate$2.19B
0.05%
114GLUE
MONTE ROSA THERAPEUTICS INCHealthcare$2.07B
0.05%
115AUPH
AURINIA PHARMACEUTICALS INCHealthcare$2.05B
0.04%
116RAPP
RAPPORT THERAPEUTICS INCHealthcare$2.04B
0.04%
117NUVB
NUVATION BIO INCHealthcare$2.03B
0.04%
118ADMA
ADMA BIOLOGICS INCHealthcare$2.02B
0.04%
119ABCL
ABCELLERA BIOLOGICS INCHealthcare$1.97B
0.04%
120AMLX
AMYLYX PHARMACEUTICALS INCHealthcare$1.97B
0.04%
121OCUL
OCULAR THERAPEUTIX INCHealthcare$1.96B
0.04%
122URGN
UROGEN PHARMA LTDHealthcare$1.96B
0.04%
123HRMY
HARMONY BIOSCIENCES HOLDINGS INCHealthcare$1.96B
0.04%
124TYRA
TYRA BIOSCIENCES INCHealthcare$1.91B
0.04%
125MRVI
MARAVAI LIFESCIENCES HOLDINGS INCHealthcare$1.87B
0.04%
126IIPR
INNOVATIVE INDUSTRIAL PROPERTIES INCReal Estate$1.86B
0.04%
127SRPT
SAREPTA THERAPEUTICS INCHealthcare$1.82B
0.04%
128STOK
STOKE THERAPEUTICS INCHealthcare$1.81B
0.04%
129ANIP
ANI PHARMACEUTICALS INCHealthcare$1.80B
0.04%
130IMCR
IMMUNOCORE HOLDINGS PLCHealthcare$1.78B
0.04%
131ZYME
ZYMEWORKS INCHealthcare$1.77B
0.04%
132HYMC
HYCROFT MINING HOLDING CORPBasic Materials$1.74B
0.04%
133HROW
HARROW INCHealthcare$1.74B
0.04%
134TSHA
TAYSHA GENE THERAPIES INCHealthcare$1.71B
0.04%
135ANAB
ANAPTYSBIO INCHealthcare$1.69B
0.04%
136INVA
INNOVIVA INCHealthcare$1.60B
0.03%
137VIR
VIR BIOTECHNOLOGY INCHealthcare$1.59B
0.03%
138NTLA
INTELLIA THERAPEUTICS INCHealthcare$1.59B
0.03%
139FOR
FORESTAR GROUP INCReal Estate$1.53B
0.03%
140XERS
XERIS BIOPHARMA HOLDINGS INCHealthcare$1.52B
0.03%
141PRGO
PERRIGO CO PLCHealthcare$1.48B
0.03%
142MLTX
MOONLAKE IMMUNOTHERAPEUTICSHealthcare$1.45B
0.03%
143PAHC
PHIBRO ANIMAL HEALTH CORPHealthcare$1.35B
0.03%
144NVAX
NOVAVAX INCHealthcare$1.35B
0.03%
145STAA
STAAR SURGICAL COHealthcare$1.32B
0.03%
146XNCR
XENCOR INCHealthcare$1.30B
0.03%
147ARDX
ARDELYX INCHealthcare$1.28B
0.03%
148INBX
INHIBRX BIOSCIENCES INCHealthcare$1.28B
0.03%
149CRVS
CORVUS PHARMACEUTICALS INCHealthcare$1.25B
0.03%
150PDM
PIEDMONT REALTY TRUST INCReal Estate$1.23B
0.03%
151QDEL
QUIDELORTHO CORPHealthcare$1.19B
0.03%
152COLL
COLLEGIUM PHARMACEUTICAL INCHealthcare$1.17B
0.03%
153ETON
ETON PHARMACEUTICALS INCHealthcare$1.16B
0.03%
154MGTX
MEIRAGTX HOLDINGS PLCHealthcare$1.15B
0.03%
155SDGR
SCHRODINGER INCHealthcare$1.14B
0.02%
156SVRA
SAVARA INCHealthcare$1.13B
0.02%
157CAPR
CAPRICOR THERAPEUTICS INCHealthcare$1.13B
0.02%
158WVE
WAVE LIFE SCIENCES LTDHealthcare$1.12B
0.02%
159ORIC
ORIC PHARMACEUTICALS INCHealthcare$1.11B
0.02%
160PCRX
PACIRA BIOSCIENCES INCHealthcare$1.01B
0.02%
161OLMA
OLEMA PHARMACEUTICALS INCHealthcare$1.00B
0.02%
162FBRX
FORTE BIOSCIENCES INCHealthcare$1.00B
0.02%
163JANX
JANUX THERAPEUTICS INCHealthcare$992M
0.02%
164VOR
VOR BIOPHARMA INCHealthcare$980M
0.02%
165MUX
MCEWEN INCBasic Materials$978M
0.02%
166ANRO
ALTO NEUROSCIENCE INCHealthcare$967M
0.02%
167KURA
KURA ONCOLOGY INCHealthcare$964M
0.02%
168ANNX
ANNEXON INCHealthcare$950M
0.02%
169TBPH
THERAVANCE BIOPHARMA INCHealthcare$873M
0.02%
170PHAT
PHATHOM PHARMACEUTICALS INCHealthcare$873M
0.02%
171AMPH
AMPHASTAR PHARMACEUTICALS INCHealthcare$871M
0.02%
172REPL
REPLIMUNE GROUP INCHealthcare$859M
0.02%
173SLDB
SOLID BIOSCIENCES INCHealthcare$859M
0.02%
174HPP
HUDSON PACIFIC PROPERTIES INCReal Estate$853M
0.02%
175CYRX
CRYOPORT INCIndustrials$832M
0.02%
176ACRS
ACLARIS THERAPEUTICS INCHealthcare$793M
0.02%
177DSGN
DESIGN THERAPEUTICS INCHealthcare$785M
0.02%
178FPH
FIVE POINT HOLDINGS LLCReal Estate$778M
0.02%
179CTO
CTO REALTY GROWTH INCReal Estate$751M
0.02%
180RIGL
RIGEL PHARMACEUTICALS INCHealthcare$750M
0.02%
181CADL
CANDEL THERAPEUTICS INCHealthcare$746M
0.02%
182AURA
AURA BIOSCIENCES INCHealthcare$723M
0.02%
183OMER
OMEROS CORPHealthcare$701M
0.02%
184SPRY
ARS PHARMACEUTICALS INCHealthcare$695M
0.02%
185CRMD
CORMEDIX INCHealthcare$661M
0.01%
186TECX
TECTONIC THERAPEUTIC INCHealthcare$615M
0.01%
187NGNE
NEUROGENE INCHealthcare$590M
0.01%
188GYRE
GYRE THERAPEUTICS INCHealthcare$587M
0.01%
189MYGN
MYRIAD GENETICS INCHealthcare$584M
0.01%
190STTK
SHATTUCK LABS INCHealthcare$577M
0.01%
191FDMT
4D MOLECULAR THERAPEUTICS INCHealthcare$575M
0.01%
192IMMX
IMMIX BIOPHARMA INCHealthcare$558M
0.01%
193CTNM
CONTINEUM THERAPEUTICS INCHealthcare$532M
0.01%
194VSTM
VERASTEM INCHealthcare$530M
0.01%
195ZURA
ZURA BIO LTDHealthcare$518M
0.01%
196ARVN
ARVINAS INCHealthcare$517M
0.01%
197DNA
GINKGO BIOWORKS HOLDINGS INCHealthcare$517M
0.01%
198RGNX
REGENXBIO INCHealthcare$511M
0.01%
199XOMA
XOMA ROYALTY CORPHealthcare$504M
0.01%
200TRC
TEJON RANCH COIndustrials$491M
0.01%
201FRPH
FRP HOLDINGS INCReal Estate$461M
0.01%
202PRTA
PROTHENA CORP PUBLIC LTD COHealthcare$453M
0.01%
203KYTX
KYVERNA THERAPEUTICS INCHealthcare$453M
0.01%
204IDR
IDAHO STRATEGIC RESOURCES INCBasic Materials$449M
0.01%
205BNTC
BENITEC BIOPHARMA INCHealthcare$439M
0.01%
206PBYI
PUMA BIOTECHNOLOGY INCHealthcare$434M
0.01%
207BOC
BOSTON OMAHA CORPCommunication Services$430M
0.01%
208ASMB
ASSEMBLY BIOSCIENCES INCHealthcare$426M
0.01%
209CBIO
CRESCENT BIOPHARMA INCHealthcare$407M
0.01%
210USNA
USANA HEALTH SCIENCES INCConsumer Defensive$403M
0.01%
211ENTA
ENANTA PHARMACEUTICALS INCHealthcare$400M
0.01%
212ABEO
ABEONA THERAPEUTICS INCHealthcare$399M
0.01%
213EBS
EMERGENT BIOSOLUTIONS INCHealthcare$394M
0.01%
214DMAC
DIAMEDICA THERAPEUTICS INCHealthcare$393M
0.01%
215STRO
SUTRO BIOPHARMA INCHealthcare$391M
0.01%
216EOLS
EVOLUS INCHealthcare$377M
0.01%
217ZNTL
ZENTALIS PHARMACEUTICALS INCHealthcare$364M
0.01%
218NATR
NATURES SUNSHINE PRODUCTS INCConsumer Defensive$359M
0.01%
219VNDA
VANDA PHARMACEUTICALS INCHealthcare$327M
0.01%
220LYEL
LYELL IMMUNOPHARMA INCHealthcare$311M
0.01%
221FHTX
FOGHORN THERAPEUTICS INCHealthcare$305M
0.01%
222TKNO
ALPHA TEKNOVA INCHealthcare$291M
0.01%
223TRDA
ENTRADA THERAPEUTICS INCHealthcare$268M
0.01%
224ARL
AMERICAN REALTY INVESTORS INCReal Estate$257M
0.01%
225QTTB
Q32 BIO INCHealthcare$255M
0.01%
226SRZN
SURROZEN INCHealthcare$255M
0.01%
227RNAC
CARTESIAN THERAPEUTICS INCHealthcare$243M
0.01%
228ARTV
ARTIVA BIOTHERAPEUTICS INCHealthcare$241M
0.01%
229KPTI
KARYOPHARM THERAPEUTICS INCHealthcare$216M
0.00%
230KROS
KEROS THERAPEUTICS INCHealthcare$211M
0.00%
231AGEN
AGENUS INCHealthcare$209M
0.00%
232IMUX
IMMUNIC INCHealthcare$207M
0.00%
233DTIL
PRECISION BIOSCIENCES INCHealthcare$203M
0.00%
234ACOG
ALPHA COGNITION INCHealthcare$185M
0.00%
235OZ
BELPOINTE PREP LLCReal Estate$181M
0.00%
236INFU
INFUSYSTEM HOLDINGS INCHealthcare$180M
0.00%
237KRRO
KORRO BIO INCHealthcare$177M
0.00%
238ARCT
ARCTURUS THERAPEUTICS HOLDINGS INCHealthcare$172M
0.00%
239STRS
STRATUS PROPERTIES INCReal Estate$165M
0.00%
240LENZ
LENZ THERAPEUTICS INCHealthcare$162M
0.00%
241RCEL
AVITA MEDICAL INCHealthcare$157M
0.00%
242UNCY
UNICYCIVE THERAPEUTICS INCHealthcare$144M
0.00%
243CUE
CUE BIOPHARMA INCHealthcare$126M
0.00%
244STHO
STAR HOLDINGSReal Estate$114M
0.00%
245USGO
US GOLDMINING INCBasic Materials$109M
0.00%
246FTLF
FITLIFE BRANDS INCConsumer Defensive$104M
0.00%
247CPIX
CUMBERLAND PHARMACEUTICALS INCHealthcare$103M
0.00%
248ICCC
IMMUCELL CORPHealthcare$101M
0.00%
249VRCA
VERRICA PHARMACEUTICALS INCHealthcare$96M
0.00%
250CSBR
CHAMPIONS ONCOLOGY INCHealthcare$85M
0.00%
251INTG
INTERGROUP CORPConsumer Cyclical$84M
0.00%
252LFVN
LIFEVANTAGE CORPConsumer Defensive$78M
0.00%
253ACET
ADICET BIO INCHealthcare$76M
0.00%
254ATRA
ATARA BIOTHERAPEUTICS INCHealthcare$76M
0.00%
255CLNN
CLENE INCHealthcare$76M
0.00%
256LONA
LEONABIO INCHealthcare$68M
0.00%
257IMA
IMAGENEBIO INCHealthcare$61M
0.00%
258XLO
XILIO THERAPEUTICS INCHealthcare$53M
0.00%
259APT
ALPHA PRO TECH LTDBasic Materials$53M
0.00%
260MCRB
SERES THERAPEUTICS INCHealthcare$52M
0.00%
261EXOZ
EXOZYMES INCHealthcare$51M
0.00%

Full long-leg book as of July 2026 · cap-weighted · total market cap $4.60T. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

8 sectors
Healthcare
97.1%
Real Estate
2.2%
Basic Materials
0.4%
Financial Services
0.2%
Consumer Cyclical
0.1%
Industrials
0.0%
Consumer Defensive
0.0%
Communication Services
0.0%

Portfolio Style

Size × value map of the long-leg book

261 classified
Value
Blend
Growth
Large
Mid
Small
4%4
40%28
49%29
1%21
2%38
2%32
<1%33
<1%31
<1%12

Share of long-leg capital by market cap × book-to-market, using terciles of the 3,283-name universe at July 2026. Rows: Large ≥ $5.2B, Small < $819M. Columns: Value ≥ 0.62, Growth < 0.34 B/M. The dot marks the capital-weighted centroid of the book — 97% toward Large, 73% toward Growth. +2% unclassified (33 missing size/value). Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt97% → Large
SmallLarge
Value ↔ growth tilt73% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 1998July 2026; the right-hand end is the same value as the box’s dot. 261 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
2
Failed
3
Not tested
2
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

2 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

  • With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.

    Required
    >= 75.0%
    Actual
    66.0%
    Margin
    -9.0%
  • No more than 25% of total assets may be invested in the securities of any one issuer.

    Required
    <= 25.0%
    Actual
    24.1%
    Margin
    0.9%

    Close to the line. The engine flags this verdict as one a routine data rebuild could flip. Read it as borderline rather than settled — the margin beside it is the whole story.

  • The fund will not concentrate: no more than 25% of total assets in any one industry (excluding government securities and cash items).

    Required
    <= 25.0%
    Actual
    97.3%
    Margin
    -72.3%
  • Days required to liquidate the largest position at 20% of one day's dollar volume.

    Required
    <= 7.0 days
    Actual
    unbounded
    Margin
Reported separately — arithmetically implied

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

1 verdict(s) sit within 1.0pp of their limit and can be flipped by a routine data rebuild; do not headline them, and always show the margin.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 261 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
1.2 (95% CI 1.0-1.3)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
11.9%
99% / 20d
Reference
9.6%
FF5 market (mkt)

historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
1.24x
within
parametric
1.06x
within
cornish fisher
1.04x
within

The estimators differ materially in value but agree on the verdict. Historical and Gaussian fund VaR differ by 16%; both still land on the same side of the 2x limit.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

published 2012
Before publication (pre-2012)
0.46
Sharpe · 7.4% p.a.
January 1999December 2012 · 168 mo
Since publication
-0.08
Sharpe · -1.2% p.a.
January 2013July 2026 · 163 mo
Change in Sharpe−0.53the return reversed sign — the published edge now runs the other way

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

26 windows
Positive windows
38%
10 of 26 3-year windows made money
Worst window
-0.98
Sharpe, January 2016 – December 2018
January 1999July 2026
Median Sharpe
-0.07
Dispersion
0.60
Best window
1.31

3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since January 1999
Trailing
PeriodLong legLong-short
1 yearcum.25.1%20.7%
3 yearsp.a.12.5%-7.0%
5 yearsp.a.4.3%-7.5%
10 yearsp.a.8.4%-4.6%
Since inceptionp.a.8.0%1.9%
Calendar years
YearLong legLong-short
20267 mo-1.5%-7.2%
202550.7%29.6%
2024-5.0%-35.4%
2023-2.0%-14.0%
2022-8.4%8.0%
202120.1%4.2%
202018.2%6.5%
201931.2%0.7%
2018-15.6%-10.1%
201718.0%-4.3%
2016-2.1%-12.3%
20152.0%15.8%
201416.0%8.2%
201333.3%-7.0%
201212.2%-11.2%
2011-3.6%-6.5%
201012.1%-2.7%
200926.4%2.0%
2008-31.7%37.1%
2007-8.1%-12.4%
200614.1%-2.0%
200510.2%4.1%
20042.6%-6.0%
200336.7%-1.5%
2002-26.2%4.5%
20010.8%45.4%
200024.8%58.7%
199945.8%5.0%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FINR
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.35% (placeholder)
Inception2020-03-23 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$4.60T

Methodology

The Foundry Investment Discipline Industry-Neutral Factor ETF tracks a rules-based model that ranks liquid U.S. common stocks, industry-neutralized within Fama-French industries, each month by a Investment Discipline signal and holds the top decile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.